Cetrelimab Uses, Dosage, Side Effects and more
Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).
| Attribute | Details |
|---|---|
| Trade Name | Cetrelimab |
| Generic | Cetrelimab |
| Cetrelimab Other Names | Cetrelimab, JNJ-63723283 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
